表紙:脆弱X症候群 (FXS) :疫学予測 (~2030年)
市場調査レポート
商品コード
948133

脆弱X症候群 (FXS) :疫学予測 (~2030年)

Fragile X Syndrome (FXS) - Epidemiology Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=136.88円
脆弱X症候群 (FXS) :疫学予測 (~2030年)
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7ヶ国市場における脆弱X症候群 (FXS) の有病率は、2017-2030年の予測期間中、CAGRが0.62%になると予測されています。性別による有病症例では、2017年の米国において、男性が40,102症例、女性は27,552症例でした。米国は、2017年に診断された脆弱X症候群 (FXS) の有病事例が最も多く、67,654例を占めています。

当レポートでは、世界の主要7市場 (米国・ドイツ・英国・イタリア・フランス・スペイン・日本) における脆弱X症候群 (FXS) 市場について調査し、市場概要、疾患の背景・疫学、各国市場などについて分析しています。

第1章 主な洞察

第2章 脆弱X症候群 (FXS) :患者の概要

  • 2017年のFXSの総患者シェア(%)分布
  • 2030年のFXSの総患者シェア(%)分布

第3章 エグゼクティブサマリー

第4章 SWOT分析

第5章 疾患の背景と概要:脆弱X症候群 (FXS)

  • イントロダクション
  • ゲノミクス
  • 症状
  • 臨床的特徴
  • 診断
  • 脆弱X症候群 (FXS) および新生児スクリーニング
    • 診断テストの推奨
    • 鑑別診断

第6章 認可施設

第7章 疫学と患者人口:脆弱X症候群 (FXS)

  • 主な調査結果
  • 主要7ヶ国における脆弱X症候群 (FXS) の総患者人口
  • 米国
    • 仮定と根拠
    • 総患者人口
    • 患者人口:性別
    • 患者人口:年齢別
  • 欧州5ヶ国
  • ドイツ
    • 総患者人口
    • 患者人口:性別
    • 患者人口:年齢別
  • フランス
  • イタリア
  • スペイン
  • 英国(UK)
  • 日本
    • 前提と根拠

第8章 KOLの見解

第9章 付録

第10章 レポートの調査手法

章11:DelveInsightのサービス内容

第12章 免責事項

第13章 DelveInsightについて

図表

List of Tables

  • Table 1: Summary of Fragile X Syndrome Epidemiology (2017-2030)
  • Table 2: Individuals for Whom Testing Should be Considered for FXS diagnosis
  • Table 3: Total Diagnosed Prevalent cases of Fragile X Syndrome in the 7MM (2017-2030)
  • Table 4: Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in the United States (2017-2030)
  • Table 5: Gender-specific Cases of Fragile X Syndrome in the United States (2017-2030)
  • Table 6: Age-specific Cases of Fragile X Syndrome in the United States (2017-2030)
  • Table 7: Total Diagnosed Prevalent Cases of FXS in Germany (2017-2030)
  • Table 8: Gender-specific Cases of Fragile X Syndrome in Germany (2017-2030)
  • Table 9: Age-Specific Cases of Fragile X Syndrome in Germany (2017-2030)
  • Table 10: Total Diagnosed Prevalent Cases of FXS in France (2017-2030)
  • Table 11: Gender-specific Cases of Fragile X Syndrome in France (2017-2030)
  • Table 12: Ages-specific Cases of Fragile X Syndrome in France (2017-2030)
  • Table 13: Total Diagnosed Prevalent Cases of FXS in Italy (2017-2030)
  • Table 14: Gender-specific Cases of Fragile X Syndrome in Italy (2017-2030)
  • Table 15: Age-specific Cases of Fragile X Syndrome in Italy (2017-2030)
  • Table 16: Total Diagnosed Prevalent Cases of FXS in Spain (2017-2030)
  • Table 17: Gender-specific Cases of Fragile X Syndrome in Spain (2017-2030)
  • Table 18: Age-specific Cases of Fragile X Syndrome in Spain (2017-2030)
  • Table 19: Total Diagnosed Prevalent Cases of FXS in the UK (2017-2030)
  • Table 20: Gender-specific Cases of Fragile X Syndrome in the UK (2017-2030)
  • Table 21: Age-specific Cases of Fragile X Syndrome in the UK (2017-2030)
  • Table 22: Total Diagnosed Prevalent Cases of FXS in Japan (2017-2030)
  • Table 23: Gender-specific Cases of Fragile X Syndrome in Japan (2017-2030)
  • Table 24: Age-specific Cases of Fragile X Syndrome in Japan (2017-2030)

List of Figures

  • Figure 1: Fragile X Syndrome (FXS) SWOT Analysis
  • Figure 2: Behavioral features of FXS
  • Figure 3: Physical features of FXS
  • Figure 4: Use of molecular techniques for FXS diagnosis
  • Figure 5: Total Diagnosed Prevalent cases of Fragile X Syndrome in the 7MM (2017-2030)
  • Figure 6: Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in the United States (2017-2030)
  • Figure 7: Gender-specific Cases of Fragile X Syndrome (FXS) in the United States (2017-2030)
  • Figure 8: Age-specific Cases of Fragile X Syndrome (FXS) in the United States (2017-2030)
  • Figure 9: Total Diagnosed Prevalent Cases of FXS in Germany (2017-2030)
  • Figure 10: Gender-specific Cases of Fragile X Syndrome (FXS) in Germany (2017-2030)
  • Figure 11: Age-specific Cases of Fragile X Syndrome (FXS) in Germany (2017-2030)
  • Figure 12: Total Diagnosed Prevalent Cases of FXS in France (2017-2030)
  • Figure 13: Gender-specific Cases of Fragile X Syndrome (FXS) in France (2017-2030)
  • Figure 14: Age-specific Cases of Fragile X Syndrome (FXS) in France (2017-2030)
  • Figure 15: Total Diagnosed Prevalent Cases of FXS in Italy (2017-2030)
  • Figure 16: Gender-specific Cases of Fragile X Syndrome (FXS) in Italy (2017-2030)
  • Figure 17: Age-specific Cases of Fragile X Syndrome (FXS) in Italy (2017-2030)
  • Figure 18: Total Diagnosed Prevalent Cases of FXS in Spain (2017-2030)
  • Figure 19: Gender-specific Cases of Fragile X Syndrome (FXS) in Spain (2017-2030)
  • Figure 20: Age-specific Cases of Fragile X Syndrome (FXS) in Spain (2017-2030)
  • Figure 21: Total Diagnosed Prevalent Cases of FXS in the UK (2017-2030)
  • Figure 22: Gender-specific Cases of Fragile X Syndrome (FXS) in the UK (2017-2030)
  • Figure 23: Age-specific Cases of Fragile X Syndrome (FXS) in the UK (2017-2030)
  • Figure 24: Total Diagnosed Prevalent Cases of FXS in Japan (2017-2030)
  • Figure 25: Gender-specific Cases of Fragile X Syndrome (FXS) in Japan (2017-2030)
  • Figure 26: Age-specific Cases of Fragile X Syndrome (FXS) in Japan (2017-2030)
目次
Product Code: DIEI0400

DelveInsight's 'Fragile X Syndrome (FXS)-Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted Fragile X Syndrome (FXS) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fragile X Syndrome (FXS) Understanding

Fragile X Syndrome is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3. It leads to a hyper-methylated region in the gene promoter, therefore, silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation.

It is considered the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome. At birth, Fragile X Syndrome neonates often exhibit no clinical signs of Fragile X Syndrome with most parameters (e.g., head circumference, weight, and height) in the normal range. In early childhood Fragile X Syndrome, physical and developmental features become more apparent, including developmental delays, psychomotor delays, intellectual disabilities, and a long face with prominent ears and flat feet. Along with biting, hand flapping, poor eye contact, language disorders from disorganized speech to complete lack of speech depending on phenotype severity can also be observed.

Fragile X Syndrome (FXS) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalence of Fragile X Syndrome in 7MM, Gender-specific Diagnosed Prevalence of Fragile X Syndrome in 7MM, Age-specific Diagnosed Prevalence of Fragile X Syndrome in 7MM, the scenario of Fragile X Syndrome (FXS) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Fragile X Syndrome (FXS) Detailed Epidemiology Segmentation

  • The prevalent population of Fragile X Syndrome in 7MM is expected to increase at a CAGR of 0.62% for the study period, i.e. 2017-2030.
  • Among the Gender-specific prevalent cases, in 2017, there were 40,102 cases of Fragile X Syndrome (FXS) in males and 27,552 cases in females, in the US.
  • The United States accounts for the highest diagnosed prevalent cases of Fragile X Syndrome with 67,654 cases in 2017

Scope of the Report:

  • The report covers the descriptive overview of Fragile X Syndrome (FXS), explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Fragile X Syndrome (FXS).
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Fragile X Syndrome (FXS), Total Diagnosed and Treated Cases of Fragile X Syndrome (FXS).

Report Highlights:

  • 11-year Forecast of Fragile X Syndrome (FXS)
  • 7MM Coverage
  • Total Diagnosed Prevalence of Fragile X Syndrome (FXS)
  • Gender-specific Prevalence of Fragile X Syndrome (FXS)
  • Age-specific Prevalence of Fragile X Syndrome (FXS)
  • The total diagnosed prevalent population of FXS in the 7MM is expected increase at a CAGR of 0.62%.
  • The United States contributed to the largest diagnosed prevalent-patient share acquiring ~57.35% of the total 7MM share in 2017

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Fragile X Syndrome (FXS)?
  • What is the historical Fragile X Syndrome (FXS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Fragile X Syndrome (FXS) at the 7MM level?
  • What will be the growth opportunities across the 7MM concerning the patient population pertaining to Fragile X Syndrome (FXS)?
  • Out of the countries mentioned above, which country would have the highest prevalent population of Fragile X Syndrome (FXS) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)? 

Reasons to buy:

The Fragile X Syndrome (FXS) report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the 7MM Fragile X Syndrome (FXS) market.
  • Quantify patient populations in the 7MM Fragile X Syndrome (FXS) market to improve product design, pricing, and launch plans.
  • The Fragile X Syndrome (FXS) epidemiology report and model are written and developed by Masters and PhD level epidemiologists.
  • The Fragile X Syndrome (FXS) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Table of Contents

1 Key Insights

2 Fragile X Syndrome (FXS): Patient Overview at a Glance

  • 2.1 Total Patient Share (%) Distribution of FXS in 2017
  • 2.2 Total Patient Share (%) Distribution of FXS in 2030

3 Executive Summary

4 SWOT Analysis

5 Disease Background and Overview: Fragile X Syndrome (FXS)

  • 5.1 Introduction
  • 5.2 Genomics
  • 5.3 Symptoms
  • 5.4 Clinical Features
  • 5.5 Diagnosis
  • 5.6 Fragile X and Newborn Screening
    • 5.6.1 Recommendation for Diagnostic Testing
    • 5.6.2 Differential Diagnosis

6 Recognized Establishments

7 Epidemiology and Patient Population: Fragile X Syndrome

  • 7.1 Key Findings
  • 7.2 Total Diagnosed Prevalent cases of Fragile X Syndrome in the 7MM
  • 7.3 United States
    • 7.3.1 Assumptions and Rationale
    • 7.3.1 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in the United States
    • 7.3.2 Gender-specific Cases of Fragile X Syndrome (FXS) in the United States
    • 7.3.3 Age-specific Cases of Fragile X Syndrome (FXS) in the United States
  • 7.4 EU5
    • 7.4.1 Assumptions and Rationale
  • 7.5 Germany
    • 7.5.1 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Germany
    • 7.5.2 Gender-specific Cases of Fragile X Syndrome (FXS) in Germany
    • 7.5.3 Age-Specific Cases of Fragile X Syndrome (FXS) in Germany
  • 7.6 France
    • 7.6.1 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in France
    • 7.6.2 Gender-specific Cases of Fragile X Syndrome (FXS) in France
    • 7.6.3 Age-specific Cases of Fragile X Syndrome (FXS) in France
  • 7.7 Italy
    • 7.7.1 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Italy
    • 7.7.2 Gender-specific Cases of Fragile X Syndrome (FXS) in Italy
    • 7.7.3 Age-specific Cases of Fragile X Syndrome (FXS) in Italy
  • 7.8 Spain
    • 7.8.1 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Spain
    • 7.8.2 Gender-specific Cases of Fragile X Syndrome (FXS) in Spain
    • 7.8.3 Age-specific Cases of Fragile X Syndrome (FXS) in Spain
  • 7.9 United Kingdom (UK)
    • 7.9.1 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in the United Kingdom
    • 7.9.2 Gender-specific Cases of Fragile X Syndrome (FXS) in the United Kingdom
    • 7.9.3 Age-specific Cases of Fragile X Syndrome (FXS) in the United Kingdom
  • 7.1 Japan
    • 7.10.1 Assumption and Rationale
    • 7.10.3 Total Diagnosed Prevalent Cases of Fragile X Syndrome (FXS) in Japan
    • 7.10.4 Gender-specific Cases of Fragile X Syndrome (FXS) in Japan
    • 7.10.5 Age-specific Cases of Fragile X Syndrome (FXS) in Japan

8 KOL Views

9 Appendix

10 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight